VetStem v. Regen Labs: Stem Cell Patent Dispute Settles in 226 Days
VetStem, Inc. sued Regen Labs LLC in California’s Central District alleging infringement of two stem cell composition patents. After 226 days of litigation, both parties reached a final settlement agreement, dismissing all claims and counterclaims with prejudice — each side absorbing its own legal costs.
Stem cell IP dispute resolved by mutual settlement in under eight months
VetStem, Inc., a California-based veterinary regenerative medicine company, filed suit against Regen Labs LLC on 26 March 2024 in the U.S. District Court for the Central District of California. The complaint alleged infringement of two patents — US9453202B2 and US11129855B2 — both directed to methods of preparing and using novel stem cell compositions and related kits. The dispute placed VetStem’s proprietary platform for adipose-derived regenerative cell therapies squarely in contest against a rival operating in an overlapping product space.
The case closed on 7 November 2024, 226 days after filing, following a jointly filed notice confirming a consummated settlement agreement. Both parties stipulated to dismissal of all claims and counterclaims with prejudice under the settlement, meaning neither party can relitigate the same claims. The cost allocation — each side bearing its own fees — is consistent with a negotiated resolution rather than a capitulation by either party, and the specific financial or licensing terms of the settlement remain confidential and are not disclosed in the public record.
The relatively swift resolution — well under one year — suggests the parties identified commercial or licensing common ground before the case reached claim construction or summary judgment, phases where litigation costs escalate sharply. Regen Labs had filed counterclaims, indicating the dispute was contested, yet both sides ultimately chose certainty over litigation risk. What drove the settlement terms, whether any cross-license or product modification was agreed, and which party bore more litigation pressure remain unknown from the public record.
Filing to Dismissed with Prejudice in 226 days
226 days — faster than the median patent case lifespan in California’s Central District, suggesting early settlement incentives.
Dismissed with prejudice: what VetStem and Regen Labs agreed to
Dismissal with prejudice bars any future refiling of these claims
A dismissal with prejudice is a final adjudication on the merits as a matter of law. Neither VetStem nor Regen Labs may re-file the same claims or counterclaims arising from this action. The settlement agreement is described as ‘consummated’ — meaning it was fully executed before the joint stipulation was filed, not merely agreed in principle. The court is not required to approve the terms, and the settlement agreement itself remains private.
Permanent bar on re-litigationVetStem secures finality without a trial — patents remain in force
VetStem’s patents — US9453202B2 and US11129855B2 — are neither invalidated nor adjudicated as infringed by any court ruling. The with-prejudice dismissal preserves their enforceability against third parties. Whether VetStem extracted a licensing fee, royalty, or product-change commitment from Regen Labs is not disclosed. The own-costs structure could reflect either a balanced negotiation or a concession by one side to close quickly, but the public record does not indicate which.
Patents remain enforceableRegen Labs exits litigation with counterclaims also dismissed
Regen Labs had filed counterclaims against VetStem — the nature of which is not detailed in the public record but commonly includes invalidity or non-infringement contentions in patent disputes. Those counterclaims are now dismissed with prejudice as well, meaning Regen Labs cannot revive them independently. The own-costs allocation suggests Regen Labs did not face a fee-shifting adverse ruling. Whether Regen Labs altered its products or obtained a license as part of the settlement is not publicly known.
Counterclaims extinguishedSettlement leaves stem cell IP landscape unresolved for the broader sector
Because no court ruled on validity or infringement, the scope of VetStem’s stem cell composition patents remains untested by judicial scrutiny. Competitors and follow-on product developers cannot draw guidance from a claim construction order or invalidity ruling here. The settlement is consistent with a pattern in biotech IP where parties prefer confidential resolution over public precedent. Other companies operating in veterinary or human regenerative cell therapy should treat these patents as active enforcement risks.
No public claim construction rulingFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Vetstem, Inc. | Company | Veterinary regenerative medicine company — holder of US9453202B2 and US11129855B2Search in Eureka ↗ |
| Defendant | Regen Labs LLC | Company | Regen Labs LLC — regenerative biology products company accused of stem cell patent infringementSearch in Eureka ↗ |
| Plaintiff counsel | Glenn S. Orman | Attorney | Counsel for Vetstem, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jonathan T. Suder | Attorney | Counsel for Vetstem, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Matthew Laurence Rollin | Attorney | Counsel for Vetstem, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Richard A. Wojcio , Jr. | Attorney | Counsel for Vetstem, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Friedman Suder & Cooke PC | Law Firm | Representing Vetstem, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sriplaw PA | Law Firm | Representing Vetstem, Inc.Search in Eureka ↗ |
| Defendant counsel | Erin A. Kelly | Attorney | Counsel for Regen Labs LLCSearch in Eureka ↗ |
| Defendant counsel | Kenneth Lee Marshall | Attorney | Counsel for Regen Labs LLCSearch in Eureka ↗ |
| Defendant law firm | Bryan Cave Leighton Paisner LLP | Law Firm | Representing Regen Labs LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | California Central District CourtSearch in Eureka ↗ |
Official order — verbatim text
The joint stipulation confirms a fully executed settlement agreement preceded the court filing — a procedurally clean exit with no judicial merits determination. The with-prejudice standard means the dismissal carries res judicata effect between these two parties on all asserted claims and counterclaims. Critically, no claim construction, invalidity ruling, or infringement finding appears in the record, which means the patents exit this litigation with their presumption of validity entirely intact and their claim scope undefined by any court order.
US9453202B2 & US11129855B2 — Stem Cell Compositions and Kits
US9453202B2 (application no. US10/575063) and US11129855B2 (application no. US16/859790) both protect innovations in the preparation, formulation, and application of stem cell compositions and associated kits. The patents sit within the adipose-derived and regenerative cell therapy space — a technically complex domain that intersects cell biology, pharmaceutical formulation, and veterinary medicine. US11129855B2, with its later application number, likely reflects a continuation or improvement on the foundational methods covered by the earlier patent, extending IP protection across a broader generation of the technology.
For competitors in veterinary or human regenerative cell therapy, these patents represent a meaningful freedom-to-operate risk. VetStem’s willingness to litigate — and to do so against a named competitor rather than a generic entity — signals an active enforcement posture. The fact that two patents were asserted together suggests VetStem structured its portfolio to create overlapping protection across core method steps and kit configurations, making design-around strategies more complex. Companies commercialising adipose-derived cell therapies or stem cell preparation kits should conduct targeted FTO analysis before market entry.
Should you run an FTO against US9453202B2 and US11129855B2?
Any company developing, manufacturing, or commercialising stem cell preparation methods, adipose-derived regenerative therapies, or therapeutic kits in veterinary or adjacent human medicine should assess exposure to these two VetStem patents. The case demonstrates VetStem’s active enforcement posture in California, and the with-prejudice settlement means no invalidity finding limits the patents’ scope. Start-ups seeking investment and incumbents launching new product lines face particular risk if their methods overlap with the claimed preparation steps.
PatSnap Eureka’s FTO Search Agent can map your product’s method steps and kit components against the independent and dependent claims of US9453202B2 and US11129855B2, flagging overlap zones and identifying prior art that could support a future IPR petition. Eureka’s claim-charting tools surface prosecution history, continuation relationships, and citation networks to help your IP and R&D teams build a defensible clearance position — or identify where design-around investment is warranted.
Run a freedom-to-operate analysis on US9453202B2 to assess your product’s exposure
Run FTO in Eureka →Similar stem cell patent infringement cases in U.S. district courts
Related patent infringement actions involving stem cell compositions and regenerative medicine methods litigated in the Central District of California and comparable federal venues.
What this case signals for the regenerative medicine IP landscape
A swift, with-prejudice settlement in stem cell patent litigation carries specific implications for freedom-to-operate and enforcement strategy in regenerative medicine.
With-prejudice settlement preserves VetStem’s enforcement position against all others
The dismissal did not narrow, invalidate, or judicially construe VetStem’s patents. US9453202B2 and US11129855B2 remain fully enforceable. Any company in the stem cell composition or regenerative kit space should treat these patents as live risk — no prior art defense or claim scope argument was validated in this case.
The own-costs structure is neutral — read nothing into who conceded first
Mutual own-costs agreements in patent settlements are common when both sides face asymmetric uncertainty. It does not indicate VetStem abandoned its claims or that Regen Labs prevailed commercially. The settlement may include undisclosed licensing, royalty, or design-around obligations that materially alter the competitive dynamic between the parties.
Vetstem v Regen — key questions answered
VetStem asserted two patents: US9453202B2 (application no. US10/575063) and US11129855B2 (application no. US16/859790). Both cover methods of preparing and using novel stem cell compositions and therapeutic kits, relevant to regenerative and adipose-derived cell therapy products.
Dismissal with prejudice means the settlement is final and neither party can re-file the same claims or counterclaims. The court entered this dismissal following a fully executed settlement agreement. VetStem’s patents are not invalidated; they remain enforceable against all third parties. Regen Labs’ counterclaims are also permanently extinguished.
The case resolved in 226 days — before typical claim construction proceedings in the Central District of California. This pace suggests the parties identified commercial or licensing common ground early, or that litigation cost-benefit analysis favoured settlement. The specific drivers are not disclosed in the public record.
The joint stipulation states each party bears its own costs and attorney’s fees. No fee-shifting award was made. This is a neutral cost allocation common in negotiated patent settlements and does not indicate either party prevailed on the merits.
Yes. US9453202B2 and US11129855B2 were not adjudicated on their merits — no invalidity, non-infringement, or claim construction ruling was issued. Both patents retain their statutory presumption of validity and remain enforceable against third parties who were not party to this settlement.
PatSnap Eureka searches patents and litigation data to answer instantly.